Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ivabradine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCN4 known ✓ | Q9Y3Q4 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | KCNN2 | Q9H2S1 | 4/20 | 0.39 |
| ▸ | KCNN3 | Q9UGI6 | 4/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ivabradine SCHEMBL23472 | 1.00 | HCN4 (1.00) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Ivabradine SCHEMBL29687794 | 1.00 | HCN4 (1.00) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Ivabradine SCHEMBL29387763 | 1.00 | HCN4 (1.00) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Ivabradine SCHEMBL5163239 | 1.00 | HCN4 (1.00) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Ivabradine SCHEMBL333200 | 1.00 | HCN4 (1.00) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Ivabradine SCHEMBL2589476 | 0.99 | HCN4 (0.98) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Ivabradine SCHEMBL29465192 | 0.99 | HCN4 (0.98) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Ivabradine SCHEMBL1032017 | 0.99 | HCN4 (0.98) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Ivabradine SCHEMBL2821678 | 0.99 | HCN4 (0.98) | HCN4CHRM2HTR1ASLC6A4DRD3 | |
| Ivabradine SCHEMBL29561458 | 0.99 | HCN4 (0.98) | HCN4CHRM2HTR1ASLC6A4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5296482-A | (Benzocycloalkyl) alkylamines | ADIR ET COMPAGNIE (FR) | 1994-03-22 | — | — | US | claimed |
| JP-5213890-A | — | — | None | — | — | JP | disclosed |
| US-8415468-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2013-04-09 | — | — | US | disclosed |
| US-8097720-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | Les Laboratories Server (FR) | 2012-01-17 | — | — | US | disclosed |
| US-20110294999-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2011-12-01 | — | — | US | disclosed |
| US-20100160628-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-06-24 | — | — | US | disclosed |
| US-5296482-A | (Benzocycloalkyl) alkylamines | ADIR ET COMPAGNIE (FR) | 1994-03-22 | — | — | US | disclosed |
| JP-H05213890-A | NEW (BENZOCYCLOALKYL) ALKYLAMINE COMPOUND | ADIR | 1993-08-24 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294999-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4F2, CYP2F1, CYP2D6 | HCN4 37/4885CHRM2 2611/4885HTR1A 1678/4885 |
| US-20100160628-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | CYP4F2, CYP2F1, CYP2D6 | HCN4 37/4885CHRM2 2611/4885HTR1A 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.